You are here

Jesse Boehm


Tseng YY, *Boehm JS*. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Curr Opin Gen Dev. 2019. Feb (54):33-40. 

Sharifnia, Tanaz et al. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem. Biol. 2017. Sept (24): 1075-1091.

Johannessen, C et al. Progress towards precision functional genomics. Curr Opin Syst Biol. 2017. Apr (2): 74-83.

Berger AH, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell. 2016 Aug 8;30(2):214-28.

Hong AL, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 Jun 22;7:11987.

Kim E, et al. Systematic functional interrogation of rare cancer variants identifies oncogenic allelesCancer Discov. 2016 Jul;6(7):714-26.

Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet. 2015 Jul;16(7):373-4.

Jesse Boehm, Ph.D.

Jesse Boehm is associate director of the Boehm Group. The Boehm group is focused on bringing the power of functional genomics to bear on living samples from cancer patients. An ultimate goal is to make “precision functional genomics” a reality for patients with rare cancers and rare genotypes. Ongoing work includes developing pipelines for personalized testing of tumor vulnerabilities as part of the CCLF, using machine learning to predict ex vivo tumor propagation conditions from the molecular features of rare tumors and using massively parallel single cell approaches to decipher the function of variants of uncertain significance.

Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences.

March 2021